Provectus Biopharmaceuticals PVCT
OTC PVCT
$0.05 +0.00 (+0.00%)
At close: Oct 21, 2026 · 4:00 PM EDT

Provectus Biopharmaceuticals (PVCT) Income from Non-Controlling Interests (2025 - 2026)

Updated

Provectus Biopharmaceuticals' Income from Non-Controlling Interests was -$6,150 in Q2 2026, compared with -$37,661 a year earlier.

Analysis

Provectus Biopharmaceuticals (PVCT) Income from Non-Controlling Interests (2025 - 2026) Analysis & Trends

On a trailing twelve-month basis, Provectus Biopharmaceuticals' Income from Non-Controlling Interests was -$58,929 through Jun 30, 2026; for FY2025, it was -$74,273.

  • In earlier years, Income from Non-Controlling Interests was -$29,585 in FY2024.
  • Quarterly Income from Non-Controlling Interests has moved between -$37,661 (Q2 2025) and -$2,770 (Q4 2025) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn -
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn -
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn 3.00 Mn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn -2.00 Mn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn -7.00 Mn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 1.00 Mn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 10.00 Mn
10 Provectus Biopharmaceuticals 21.01 Mn 19.10 Mn - -6,150.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6,150.00
Dec 31, 2025 -2,770.00
Sep 30, 2025 -12,348.00
Jun 30, 2025 -37,661.00
Mar 31, 2025 -21,494.00
API Access

Provectus Biopharmaceuticals Income from Non-Controlling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=PVCT&period=max&api_key=YOUR_API_KEY